Pain Report #13 End-of-Life Care: The Management of Pain in Palliative Medicine

Release Date: June 30, 2011
Expiration Date: June 30, 2013

Supported by Purdue Pharma, L.P.

Intended Audience

Nurse Practitioners, Pharmacists, Physicians, Physician Assistants, Registered Nurses

Learning Objectives

Upon completion of this activity, the participant should be able to:

Communicate a historical perspective of hospice and national guidelines for quality palliative care
Categorize common types of pain syndromes, assessment tools and potential therapeutic options
Define the pharmacology of opiates and neuroplasty
Discuss challenges and barriers to effective pain management

Statement of Need

The end stage of life is often characterized with pain and suffering. As the most experienced and feared symptom at the end of life, pain is often undertreated, even though it can be controlled in the vast majority of cases. Healthcare professionals should have a better understanding of the objectives of palliative care and options available for patients and caregivers when treating patients at the end of life.

Method of Participation

This activity has no fee and should take approximately one hour to complete. Participants should first read the objectives and other introductory CE information, then proceed to the educational offering. To receive credit for this activity, participants must complete the post-test with a passing score of 80%, then complete the evaluation. This credit is valid through June 30, 2013. No credit will be given after this date.

In the event you have questions about this activity or are unable to print the certificate, please email cme@dannemiller.com and a certificate will be emailed within 2 weeks.

System requirements

Computer or smart phone with internet access
Web browser (IE 7.0+ or Webkit/Mozilla Compatible) with Javascript enabled

Accreditation

Dannemiller is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians

Dannemiller designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nurses

Dannemiller is a provider approved by the California Board of Registered Nursing, Provider Number 4229 for 1.00 contact hours.
RNs outside of California must verify with their licensing agency for approval of this course.

Nurse Practitioners

Dannemiller is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 090419. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. It provides 1.00 contact hours of continuing education (which includes 0.50 hours of pharmacology).

Physician Assistants

AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.00 AMA PRA Category 1 Credit(s)™ for completing this program.

Pharmacists

Dannemiller is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is a knowledge based activity. Dannemiller has assigned 1.00 contact hours (0.10 CEU) of continuing pharmacy education credit to this activity. ACPE program number 0522-0000-11-005-H01-P.

Faculty

Alexander Peralta, Jr., MD DABHPM
President, Palliative Medicine Consulting Services
and Palliative Medicine Seminars
Duncanville, Texas

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.

The following faculty stated that hey have no relevant financial disclosure:

Alexander Peralta, Jr., MD

Dannemiller staff, Barbra Thompson, Publications Project Manager, has nothing to disclose.

To resolve identified conflicts of interest, the educational content was fully reviewed by Bernard Abrams, MD, Dannemiller Medical Director, who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

Off-label statement

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

Begin this activity